Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 8/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 3/20 | 0.36 |
| ▸ | ACACA | Q13085 | 4/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | F7 | P08709 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12807206 | 1.00 | ACACB (0.37) | ACACBALDH1A1HTTNPSR1RORC | |
| SCHEMBL1677905 | 1.00 | ACACB (0.37) | ACACBALDH1A1HTTNPSR1RORC | |
| SCHEMBL1677556 | 0.90 | ALDH1A1 (0.38) | ACACBALDH1A1HTTNPSR1GCK | |
| SCHEMBL1083112 | 0.90 | ALDH1A1 (0.38) | ACACBALDH1A1HTTNPSR1GCK | |
| SCHEMBL15576381 | 0.90 | ALDH1A1 (0.38) | ACACBALDH1A1HTTNPSR1GCK | |
| SCHEMBL12734100 | 0.89 | ACACB (0.40) | ACACBACACA | |
| SCHEMBL1082996 | 0.87 | ALDH1A1 (0.39) | ACACBALDH1A1HTTNPSR1ACACA | |
| SCHEMBL1677264 | 0.87 | ALDH1A1 (0.39) | ACACBALDH1A1HTTNPSR1ACACA | |
| SCHEMBL12807186 | 0.87 | ALDH1A1 (0.39) | ACACBALDH1A1HTTNPSR1ACACA | |
| SCHEMBL564741 | 0.83 | GCK (0.38) | ACACBALDH1A1HTTNPSR1GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673942-B2 | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
| EP-2276760-A1 | FUSED RING COMPOUNDS AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009125873-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | GCKR, GPR119, SLC5A1 | ACACB 695/4885ALDH1A1 305/4885HTT 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.